Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
This is a 400 mg (2 x 200 mg tablets) sorafenib single dose, open-label study being conducted
to compare the pharmacokinetics of plasma and urine and safety of sorafenib in subjects with
severe, moderate, and mild renal impairment with those exhibiting normal renal function.